QazCovid-in

QazCovid-in is a vaccine developed by the Research Institute for Biological Safety Problems (RIBSP) in Kazakhstan for the prevention of COVID-19. The vaccine is an inactivated vaccine, meaning it uses a non-infectious version of the SARS-CoV-2 virus to stimulate an immune response.

Development

The development of QazCovid-in began in early 2020, shortly after the COVID-19 pandemic began. The RIBSP, a government-funded institute, led the research and development efforts. The vaccine underwent three phases of clinical trials to assess its safety and efficacy. The trials involved thousands of participants and took place in multiple locations across Kazakhstan.

Efficacy

The efficacy of QazCovid-in is reported to be around 96%, according to data from the phase III clinical trials. This means that the vaccine is highly effective at preventing COVID-19 in those who receive it. However, it's important to note that efficacy can vary depending on a number of factors, including the individual's age, health status, and exposure to the virus.

Distribution

The distribution of QazCovid-in began in early 2021, with priority given to healthcare workers and other high-risk groups. The vaccine is administered in two doses, with a gap of 21 days between each dose. As of now, the vaccine is only available in Kazakhstan, but there are plans to expand distribution to other countries in the future.

Side Effects

Like all vaccines, QazCovid-in can cause side effects. The most common side effects are mild and include pain at the injection site, fatigue, headache, muscle pain, and fever. Serious side effects are rare, but can include allergic reactions.

See Also

• COVID-19 vaccine
• COVID-19 pandemic in Kazakhstan
• Inactivated vaccine
• Clinical trial

References

<references />

   This article is a  stub. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!